

# Fabrizio Luppi

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/371092/fabrizio-luppi-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

117  
papers

2,706  
citations

27  
h-index

49  
g-index

134  
ext. papers

3,370  
ext. citations

5.5  
avg, IF

4.93  
L-index

#	Paper	IF	Citations
117	Idiopathic pulmonary fibrosis mortality in the Italian epicenter of COVID-19 pandemic.. <i>Pulmonology</i> , <b>2022</b> ,	3.7	1
116	Feasibility of CPAP application and variables related to worsening of respiratory failure in pregnant women with SARS-CoV-2 pneumonia: Experience of a tertiary care centre. <i>PLoS ONE</i> , <b>2021</b> , 16, e0258754	3.7	0
115	Usefulness of digital velcro crackles detection in identification of interstitial lung disease in patients with connective tissue diseases. <i>Archives of Rheumatology</i> , <b>2021</b> , 36, 19-25	0.9	2
114	Subclinical liver fibrosis in patients with idiopathic pulmonary fibrosis. <i>Internal and Emergency Medicine</i> , <b>2021</b> , 16, 349-357	3.7	1
113	Idiopathic pulmonary fibrosis beyond the lung: understanding disease mechanisms to improve diagnosis and management. <i>Respiratory Research</i> , <b>2021</b> , 22, 109	7.3	11
112	Rheumatoid arthritis related interstitial lung disease. <i>Expert Review of Clinical Immunology</i> , <b>2021</b> , 17, 485-497	5.1	1
111	POS1228 THE ROLE OF CHEST CT IN UNDERSTANDING INTERSTITIAL LUNG DISEASE (ILD): SYSTEMIC SCLEROSIS (SSc). VERSUS COVID-19. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 897.2-898	2.4	
110	Patient-reported outcomes and patient-reported outcome measures in interstitial lung disease: where to go from here?. <i>European Respiratory Review</i> , <b>2021</b> , 30,	9.8	2
109	Feasibility and clinical impact of a portable bi-level ventilation device in patients with severe chronic obstructive pulmonary disease and exertional dyspnea: preliminary results from a clinical series. <i>Physiotherapy Theory and Practice</i> , <b>2021</b> , 1-5	1.5	
108	Diagnosis and Management of Fibrotic Interstitial Lung Diseases. <i>Clinics in Chest Medicine</i> , <b>2021</b> , 42, 321-335	3.5	0
107	Molecular Biomarkers in Idiopathic Pulmonary Fibrosis: State of the Art and Future Directions. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	3
106	Fibrosing interstitial lung disease in primary Sjogren syndrome. <i>Joint Bone Spine</i> , <b>2021</b> , 88, 105237	2.9	0
105	Nontuberculous mycobacterial pulmonary disease: an integrated approach beyond antibiotics. <i>ERJ Open Research</i> , <b>2021</b> , 7,	3.5	4
104	THE ROLE OF CHEST CT IN DECIPHERING INTERSTITIAL LUNG INVOLVEMENT: SYSTEMIC SCLEROSIS VERSUS COVID-19. <i>Rheumatology</i> , <b>2021</b> ,	3.9	15
103	Six-Month Pulmonary Impairment after Severe COVID-19: A Prospective, Multicentre Follow-Up Study. <i>Respiration</i> , <b>2021</b> , 100, 1078-1087	3.7	7
102	Interstitial lung disease in ANCA-associated vasculitis: another step forward. <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> , 39 Suppl 129, 193	2.2	
101	Reply to the comment on: Hypereosinophilic bronchiolitis in ANCA-associated vasculitis: where does it stand? by Bilgin et al. <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> , 39 Suppl 129, 197	2.2	

100	Reply to the comment on: Hypereosinophilic bronchiolitis in ANCA-associated vasculitis: where does it stand? by Bilgin et al.. <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> , 39, 197-197	2.2	
99	Interstitial lung disease in ANCA-associated vasculitis: another step forward. <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> , 39, 193-193	2.2	0
98	Disease progression across the spectrum of idiopathic pulmonary fibrosis: A multicentre study. <i>Respirology</i> , <b>2020</b> , 25, 1144-1151	3.6	3
97	Rehospitalization for pneumonia after first pneumonia admission: Incidence and predictors in a population-based cohort study. <i>PLoS ONE</i> , <b>2020</b> , 15, e0235468	3.7	2
96	Treatment of Rheumatoid Arthritis-Associated Interstitial Lung Disease: Lights and Shadows. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	33
95	Ventilatory support and mechanical properties of the fibrotic lung acting as a "squishy ball". <i>Annals of Intensive Care</i> , <b>2020</b> , 10, 13	8.9	14
94	Erratum to acute exacerbation of interstitial lung diseases secondary to systemic rheumatic diseases: a prospective study and review of the literature. <i>Journal of Thoracic Disease</i> , <b>2020</b> , 12, 6411-6416		
93	Interstitial Pneumonia with Autoimmune Features: Why Rheumatologist-Pulmonologist Collaboration Is Essential. <i>Biomedicines</i> , <b>2020</b> , 9,	4.8	7
92	Interstitial pneumonia with autoimmune features: A single center prospective follow-up study. <i>Autoimmunity Reviews</i> , <b>2020</b> , 19, 102451	13.6	17
91	Functional Progression in Patients with Interstitial Lung Disease Resulted Positive to Antisynthetase Antibodies: A Multicenter, Retrospective Analysis. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	2
90	Progressive Fibrosing Interstitial Lung Diseases: Prevalence and Characterization in Two Italian Referral Centers. <i>Respiration</i> , <b>2020</b> , 99, 838-845	3.7	9
89	Pathogenesis and treatment of idiopathic and rheumatoid arthritis-related interstitial pneumonia. The possible lesson from COVID-19 pneumonia. <i>Expert Review of Clinical Immunology</i> , <b>2020</b> , 16, 751-770	5.1	7
88	Lung complications of Sjogren syndrome. <i>European Respiratory Review</i> , <b>2020</b> , 29,	9.8	12
87	What Patients With Idiopathic Pulmonary Fibrosis and Caregivers Want: Filling the Gaps With Patient Reported Outcomes and Experience Measures. <i>American Journal of Medicine</i> , <b>2020</b> , 133, 281-289	2.4	18
86	Janus-faced amiodarone-induced pneumopathy. <i>Pulmonology</i> , <b>2020</b> , 26, 101-103	3.7	1
85	Epidemiology and management of interstitial lung disease in ANCA-associated vasculitis. <i>Clinical and Experimental Rheumatology</i> , <b>2020</b> , 38 Suppl 124, 221-231	2.2	11
84	Interstitial lung disease in Sjogren syndrome: a clinical review. <i>Clinical and Experimental Rheumatology</i> , <b>2020</b> , 38 Suppl 126, 291-300	2.2	6
83	Rehospitalization for pneumonia after first pneumonia admission: Incidence and predictors in a population-based cohort study <b>2020</b> , 15, e0235468		

82	Rehospitalization for pneumonia after first pneumonia admission: Incidence and predictors in a population-based cohort study <b>2020</b> , 15, e0235468		
81	Rehospitalization for pneumonia after first pneumonia admission: Incidence and predictors in a population-based cohort study <b>2020</b> , 15, e0235468		
80	Rehospitalization for pneumonia after first pneumonia admission: Incidence and predictors in a population-based cohort study <b>2020</b> , 15, e0235468		
79	Rehospitalization for pneumonia after first pneumonia admission: Incidence and predictors in a population-based cohort study <b>2020</b> , 15, e0235468		
78	Rehospitalization for pneumonia after first pneumonia admission: Incidence and predictors in a population-based cohort study <b>2020</b> , 15, e0235468		
77	Pirfenidone in real life: A retrospective observational multicentre study in Italian patients with idiopathic pulmonary fibrosis. <i>Respiratory Medicine</i> , <b>2019</b> , 156, 78-84	4.6	14
76	Antifibrotic treatment response and prognostic predictors in patients with idiopathic pulmonary fibrosis and exposed to occupational dust. <i>BMC Pulmonary Medicine</i> , <b>2019</b> , 19, 170	3.5	
75	Early referral to palliative care services in patients with IPF: a tool to take a step forward. <i>BMJ Supportive and Palliative Care</i> , <b>2019</b> ,	2.2	1
74	The prognostic role of Gender-Age-Physiology system in idiopathic pulmonary fibrosis patients treated with pirfenidone. <i>Clinical Respiratory Journal</i> , <b>2019</b> , 13, 166-173	1.7	4
73	Acute exacerbation of interstitial lung diseases secondary to systemic rheumatic diseases: a prospective study and review of the literature. <i>Journal of Thoracic Disease</i> , <b>2019</b> , 11, 1621-1628	2.6	23
72	Diagnostic accuracy of a velcro sound detector (VECTOR) for interstitial lung disease in rheumatoid arthritis patients: the InSPIRAtE validation study (INterStitial pneumonia in rheumatoid ArThritis with an electronic device). <i>BMC Pulmonary Medicine</i> , <b>2019</b> , 19, 111	3.5	24
71	Nintedanib and Sildenafil in Patients with Idiopathic Pulmonary Fibrosis and Right Heart Dysfunction. A Prespecified Subgroup Analysis of a Double-Blind Randomized Clinical Trial (INSTAGE). <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2019</b> , 200, 1505-1512	10.2	30
70	Real-life comparison of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis: A 24-month assessment. <i>Respiratory Medicine</i> , <b>2019</b> , 159, 105803	4.6	20
69	Multidisciplinary approach to systemic diseases: benefits for diagnosis and management of complex disorders <b>2019</b> , 1-13		2
68	Clinical differences in sarcoidosis patients with and without lymphoma: a single-centre retrospective cohort analysis. <i>European Respiratory Journal</i> , <b>2019</b> , 54,	13.6	4
67	Pretreatment rate of decay in forced vital capacity predicts long-term response to pirfenidone in patients with idiopathic pulmonary fibrosis. <i>Scientific Reports</i> , <b>2018</b> , 8, 5961	4.9	10
66	Best supportive care for idiopathic pulmonary fibrosis: current gaps and future directions. <i>European Respiratory Review</i> , <b>2018</b> , 27,	9.8	24
65	Analysis of pulmonary sounds for the diagnosis of interstitial lung diseases secondary to rheumatoid arthritis. <i>Computers in Biology and Medicine</i> , <b>2018</b> , 96, 91-97	7	12

64	A Real-Life Multicenter National Study on Nintedanib in Severe Idiopathic Pulmonary Fibrosis. <i>Respiration</i> , <b>2018</b> , 95, 433-440	3.7	31
63	"Velcro-type" crackles predict specific radiologic features of fibrotic interstitial lung disease. <i>BMC Pulmonary Medicine</i> , <b>2018</b> , 18, 103	3.5	22
62	Acute exacerbation of idiopathic pulmonary fibrosis: lessons learned from acute respiratory distress syndrome?. <i>Critical Care</i> , <b>2018</b> , 22, 80	10.8	37
61	Management of Idiopathic Pulmonary Fibrosis <b>2018</b> , 55-63		1
60	Healthcare utilisation and costs in the diagnosis and treatment of progressive-fibrosing interstitial lung diseases. <i>European Respiratory Review</i> , <b>2018</b> , 27,	9.8	10
59	High serum levels of silica nanoparticles in systemic sclerosis patients with occupational exposure: Possible pathogenetic role in disease phenotypes. <i>Seminars in Arthritis and Rheumatism</i> , <b>2018</b> , 48, 475-481	5.3	17
58	Prevalence and characterization of non-sicca onset primary Sjögren syndrome with interstitial lung involvement. <i>Clinical Rheumatology</i> , <b>2017</b> , 36, 1261-1268	3.9	40
57	Effectiveness of pulmonary rehabilitation in patients with interstitial lung disease of different etiology: a multicenter prospective study. <i>BMC Pulmonary Medicine</i> , <b>2017</b> , 17, 130	3.5	39
56	Predicting the future of patients with idiopathic pulmonary fibrosis: another step forward. <i>Lancet Respiratory Medicine</i> , <b>2017</b> , 5, 911-913	35.1	1
55	Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers?. <i>Lancet Respiratory Medicine</i> , <b>2017</b> , 5, 591-598	35.1	47
54	Interstitial pneumonia with autoimmune features and undifferentiated connective tissue disease: Our interdisciplinary rheumatology-pneumology experience, and review of the literature. <i>Autoimmunity Reviews</i> , <b>2016</b> , 15, 61-70	13.6	56
53	Evaluation of serum (1- $\beta$ )-D-glucan clinical performance: kinetic assessment, comparison with galactomannan and evaluation of confounding factors. <i>Infection</i> , <b>2016</b> , 44, 223-33	5.8	23
52	Occurrence of idiopathic pulmonary fibrosis during immunosuppressive treatment: a case report. <i>Journal of Medical Case Reports</i> , <b>2016</b> , 10, 127	1.2	2
51	Pulmonary Carcinosarcoma Arising in the Framework of an Idiopathic Pulmonary Fibrosis. <i>Lung</i> , <b>2016</b> , 194, 171-3	2.9	3
50	Radiologic classification of usual interstitial pneumonia in rheumatoid arthritis-related interstitial lung disease: correlations with clinical, serological and demographic features of disease. <i>Clinical and Experimental Rheumatology</i> , <b>2016</b> , 34, 564-5	2.2	6
49	Clinical performance of a commercial real-time PCR assay for Aspergillus DNA detection in serum samples from high-risk patients: comparison with a galactomannan enzyme immunoassay. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , <b>2015</b> , 34, 131-136	5.3	20
48	Acute exacerbation of idiopathic pulmonary fibrosis: a clinical review. <i>Internal and Emergency Medicine</i> , <b>2015</b> , 10, 401-11	3.7	26
47	Levels of circulating endothelial cells are low in idiopathic pulmonary fibrosis and are further reduced by anti-fibrotic treatments. <i>BMC Medicine</i> , <b>2015</b> , 13, 277	11.4	21

46	Antibiotic treatment of severe exacerbations of chronic obstructive pulmonary disease with procalcitonin: a randomized noninferiority trial. <i>PLoS ONE</i> , <b>2015</b> , 10, e0118241	3.7	31
45	Predictive value of isolated DLCO reduction in systemic sclerosis patients without cardio-pulmonary involvement at baseline. <i>Reumatismo</i> , <b>2015</b> , 67, 149-55	1.1	3
44	Efficacy of pirfenidone for idiopathic pulmonary fibrosis: An Italian real life study. <i>Respiratory Medicine</i> , <b>2015</b> , 109, 904-13	4.6	58
43	Mindfulness-based stress reduction in patients with interstitial lung diseases: a pilot, single-centre observational study on safety and efficacy. <i>BMJ Open Respiratory Research</i> , <b>2015</b> , 2, e000065	5.6	13
42	Detection of <i>Pneumocystis jirovecii</i> and <i>Aspergillus</i> spp. DNA in bronchoalveolar lavage fluids by commercial real-time PCR assays: comparison with conventional diagnostic tests. <i>New Microbiologica</i> , <b>2015</b> , 38, 75-84	1.1	20
41	Pathology of COPD and Asthma <b>2014</b> , 25-36		1
40	Primary endpoints in phase 3 clinical trials in idiopathic pulmonary fibrosis: one step at a time. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2013</b> , 187, 1271-2	10.2	4
39	Bradykinin-induced asthmatic fibroblast/myofibroblast activities via bradykinin B2 receptor and different MAPK pathways. <i>European Journal of Pharmacology</i> , <b>2013</b> , 710, 100-9	5.3	25
38	Prognostic role of clusterin in resected adenocarcinomas of the lung. <i>Lung Cancer</i> , <b>2013</b> , 79, 294-9	5.9	15
37	Lung cancer in scleroderma: results from an Italian rheumatologic center and review of the literature. <i>Autoimmunity Reviews</i> , <b>2013</b> , 12, 374-9	13.6	40
36	Improvement in tubercular cavities following adjuvant treatment with endobronchial valves: a case report. <i>International Journal of Tuberculosis and Lung Disease</i> , <b>2013</b> , 17, 850-1	2.1	3
35	The reply. <i>American Journal of Medicine</i> , <b>2013</b> , 126, e19	2.4	23
34	Clinical trials of idiopathic pulmonary fibrosis: choosing the (right) primary end point. <i>Clinical Investigation</i> , <b>2013</b> , 3, 1139-1146		
33	BPCO e altre malattie polmonari croniche. <i>Italian Journal of Medicine</i> , <b>2012</b> , 6, 265-275	0.5	
32	Sarcoidosis: challenging diagnostic aspects of an old disease. <i>American Journal of Medicine</i> , <b>2012</b> , 125, 118-25	2.4	32
31	Genetic testing in diffuse parenchymal lung disease. <i>Orphanet Journal of Rare Diseases</i> , <b>2012</b> , 7, 79	4.2	5
30	Management of idiopathic pulmonary fibrosis. <i>Clinics in Chest Medicine</i> , <b>2012</b> , 33, 85-94	5.3	7
29	The big clinical trials in idiopathic pulmonary fibrosis. <i>Current Opinion in Pulmonary Medicine</i> , <b>2012</b> , 18, 428-32	3	27

28	Linee guida sulla BPCO non associata a comorbilità croniche. <i>Italian Journal of Medicine</i> , <b>2011</b> , 5, 14-21	0.5	
27	Le infezioni come comorbilità della BPCO. <i>Italian Journal of Medicine</i> , <b>2011</b> , 5, 135-141	0.5	
26	Bronchoalveolar lavage and response to cyclophosphamide in scleroderma alveolitis. <i>Scandinavian Journal of Rheumatology</i> , <b>2010</b> , 39, 155-9	1.9	2
25	Acute exacerbations of chronic obstructive pulmonary disease: are antibiotics needed?. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2010</b> , 181, 102-3	10.2	6
24	Non-steroid agents for idiopathic pulmonary fibrosis. <i>The Cochrane Library</i> , <b>2010</b> , CD003134	5.2	66
23	Cellular non-specific interstitial pneumonia as a pulmonary manifestation of primary biliary cirrhosis. <i>Pathology</i> , <b>2010</b> , 42, 596-8	1.6	3
22	Performance of tests for latent tuberculosis in different groups of immunocompromised patients. <i>Chest</i> , <b>2009</b> , 136, 198-204	5.3	119
21	To BAL or not to BAL: is this a problem in diagnosing IPF?. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2009</b> , 180, 379-80; author reply 380	10.2	4
20	EGFR and K-ras mutations along the spectrum of pulmonary epithelial tumors of the lung and elaboration of a combined clinicopathologic and molecular scoring system to predict clinical responsiveness to EGFR inhibitors. <i>American Journal of Clinical Pathology</i> , <b>2009</b> , 131, 478-89	1.9	64
19	Clusterin (CLU) and lung cancer. <i>Advances in Cancer Research</i> , <b>2009</b> , 105, 63-76	5.9	34
18	Diagnosis of Asthma and COPD <b>2009</b> , 523-541		
17	Endogenous blood maximal interferon-gamma production may predict response to interferon-gamma 1beta treatment in patients with idiopathic pulmonary fibrosis. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , <b>2009</b> , 26, 64-8	1.1	3
16	Complex chronic comorbidities of COPD. <i>European Respiratory Journal</i> , <b>2008</b> , 31, 204-12	13.6	433
15	Role of comorbidities in a cohort of patients with COPD undergoing pulmonary rehabilitation. <i>Thorax</i> , <b>2008</b> , 63, 487-92	7.3	186
14	Treatment of chronic obstructive pulmonary disease and its comorbidities. <i>Proceedings of the American Thoracic Society</i> , <b>2008</b> , 5, 848-56		25
13	Interleukin-8 stimulates cell proliferation in non-small cell lung cancer through epidermal growth factor receptor transactivation. <i>Lung Cancer</i> , <b>2007</b> , 56, 25-33	5.9	167
12	Epithelial responses to oxidative stress in chronic obstructive pulmonary disease: lessons from expression profiling. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2007</b> , 175, 527-8	10.2	10
11	Update in chronic obstructive pulmonary disease 2006. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2007</b> , 175, 1222-32	10.2	69

10	Update in chronic obstructive pulmonary disease 2005. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2006</b> , 173, 1056-65	10.2	27
9	Pathophysiology of exacerbations of chronic obstructive pulmonary disease. <i>Proceedings of the American Thoracic Society</i> , <b>2006</b> , 3, 245-51		125
8	Clusterin decreases oxidative stress in lung fibroblasts exposed to cigarette smoke. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2006</b> , 174, 393-9	10.2	35
7	Diagnosis of occult tuberculosis in hematological malignancy by enumeration of antigen-specific T cells. <i>Leukemia</i> , <b>2006</b> , 20, 379-81	10.7	17
6	Effects of cigarette smoke condensate on proliferation and wound closure of bronchial epithelial cells in vitro: role of glutathione. <i>Respiratory Research</i> , <b>2005</b> , 6, 140	7.3	99
5	Management of fixed airflow limitation caused by asthma or chronic obstructive pulmonary disease. <i>Clinical and Experimental Allergy Reviews</i> , <b>2004</b> , 4, 205-211		
4	Corticosteroid and immunomodulatory agents in idiopathic pulmonary fibrosis. <i>Respiratory Medicine</i> , <b>2004</b> , 98, 1035-44	4.6	28
3	Corticosteroids for idiopathic pulmonary fibrosis. <i>The Cochrane Library</i> , <b>2003</b> , CD002880	5.2	95
2	New therapeutic indications for Cys-LT1 antagonists: chronic obstructive pulmonary disease. <i>Clinical and Experimental Allergy Reviews</i> , <b>2001</b> , 1, 166-169		
1	Die idiopathische pulmonale Fibrose jenseits der Lunge: Krankheitsmechanismen verstehen, um Diagnose und Therapie zu verbessern. <i>Karger Kompass Pneumologie</i> , 1-12	0	